Latest Financials News

Emyria reported $1.2 million revenue for Q1 2026 driven by insurer-funded clinics and expanded its Empax network across multiple states. It launched a Global Partnership Program targeting international drug sponsors, leveraging its clinical infrastructure amid growing global interest in psychedelic therapies.

CZR Resources has launched a new drilling campaign at its Croydon Gold Project, focusing on extending known mineralisation and testing for high-grade ore shoots and Hemi-style intrusions. The program leverages recent geological insights and a robust $67 million cash position.

Etherstack has smashed its first half revenue record for FY26 with strong government contract deliveries, prompting an upward revision of full-year revenue guidance to as much as US$18.9 million.

Chilwa Minerals confirmed a significant niobium discovery at its Nakombe target, progressing with dual diamond rig drilling and advancing a NASDAQ listing application. Heavy mineral sands resource work continues alongside a new ionic clay rare earth program.

Centaurus Metals has secured a binding offtake deal with Glencore and attracted up to US$320 million in financing offers for its Jaguar Nickel Project, while advancing exploration and pilot testing at its Brazilian copper-gold and iron ore assets.

VBX Limited has more than doubled the Measured and Indicated Mineral Resource at its Wuudagu bauxite project to 131.9 million tonnes with improved grades, while also enhancing its Definitive Feasibility Study scope and securing additional funding.

AusQuest has confirmed a vast copper-gold system at its Cangallo project in Peru, revealing broad mineralisation and multiple higher-grade zones. Meanwhile, exploration momentum continues in Australia under a South32 alliance, with key drilling programs poised to start.

Biome Australia’s Activated Probiotics brand surpasses one million boxes sold in Australia, approaches top pharmacy ranking, and launches nationally in Canada, setting the stage for FY26 profitability.

PYC Therapeutics fortified its balance sheet by $600 million and progressed key RNA therapeutic trials in Q1 2026, setting the stage for pivotal clinical data and regulatory submissions.

Central Petroleum lifted March quarter sales revenue to $11.3 million, driven by higher gas volumes and prices, while securing a significant multi-year gas supply deal with the Northern Territory Government that supports a 40% production capacity increase at Palm Valley.

Cambium Bio has clinched FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development complexity, while bolstering its cash position through a A$2.4 million strategic placement by major shareholder ZYBT.

Mammoth Minerals reported significant shallow gold intercepts at its Excelsior Springs project in Nevada, expanded its landholding with the Imperial Gold Project acquisition, and completed the Paterson divestment, positioning itself for further exploration growth.